MindMed (MNMD.Q) will participate and assist in the financing of the Digital Medicine Society’s (DiMe) Digital Health Measurement Collaborative Community (DATAcc) in the development of best practices, and the streamlining of measurements for health using digital technologies.
Here are the core three questions the DATAcc shows on their website:
- How do we ensure that we use digital measures to improve individuals’ care, not violate their privacy?
- How do we ensure that we can take a data-driven approach to public health without facilitating harmful surveillance?
- How do we use digital health measures to improve access to care and health equity, not exacerbate these challenges along the digital divide?
All three of which are questions worth tackling as we roll deeper into the 21st century and its individual and collective challenges. Beyond those, though, we have the core problems in the amalgamation of tech and medical science: how do we minimize harm?
“Historically, medicine has relied on infrequent, subjective, physician oriented measurements, which are largely carried out in the clinical setting. This is especially true in psychiatry. The reality is that illnesses, and the burdens they place on the patient experience, have far more to do with how folks feel and function when they’re in their home environments and not in the clinic. We see digital medicine and real world measurement as being core to better understanding the conditions we are studying for treatment with psychedelic-inspired medicines, and demonstrating that our medicines are effective in helping treat individual suffering while reducing the myriad costs of these illnesses through enabling patient journeys toward recovery,” said Dr. Dan Karlin, chief medical officer for MindMed.
MindMed is a biotech company involved in the discovery, development and proliferation of psychedelic medicines and therapies for addiction and mental health. Their latest task is to assemble a compelling drug development pipeline using psychedelics, including psilocybin, LSD, MDMA, DMT and 18-MC, an ibogaine derivative.
Respectively, the DATAcc draws its leadership from both the private and public sectors, including not only the United States government and non-profits, but also the FDA, US Department of Health and Human Services, medical tech companies, biopharma and patient advocates. Members, including Karlin, and will meet today to make the launch of this community. The collaborative will use interdisciplinary expertise, data, and cases to address complex medical device challenges.
“It is important to empower stakeholders to ensure equitable access to high quality, safe, and effective digital health technologies. DATAcc can advance efforts to build the science and evidence generation for all people by keeping health outcomes and health equity front and center,” said Anindita Saha, assistant director of the Digital Health Center of Excellence in the Center for Devices and Radiological Health, the FDA liaison to DATAcc in a press release.
The collaborative community will explore six areas, including data governance, data rights, digital inclusion, reimbursement, commercial models and the standardization of elements of digital sensing products and the data they produce.
MindMed is down $0.06 today, trading at $3.01.
—Joseph Morton
